1. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial 
James W. Welsh, MD, Steven N. Seyedin, MD, Pamela K. Allen, PhD, Wayne L. Hofstetter, MD, Jaffer A. Ajani, MD, Joe Y. Chang, MD, PhD, Daniel R. Gomez, MD, Arya Amini, MD, Stephen G. Swisher, MD, Mariela A. Blum, MD, Ahmed I. Younes, MD, Quynh-Nhu Nguyen, MD, Bruce D. Minsky, MD, Jeremy J. Erasmus, MD, Jeffrey H. Lee, MD, Manoop Bhutani, MD, Ritsuko U. Komaki, MD 
Journal of Thoracic Oncology 
Volume 12, Issue 2, Pages (February 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
First sites of failure among patients with esophageal cancer who received a simultaneous integrated boost (dose escalation) to 63 Gy to the gross tumor volume by intensity-modulated radiation therapy and a comparison group who received intensity-modulated radiation therapy to 50.4 Gy without a boost dose. NED, no evidence of disease.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Local failure–free survival proportions according to whether patients received a boost dose to the gross tumor volume (dose escalation) or a conventional dose of 50.4 Gy for locally advanced esophageal cancer, both delivered as intensity-modulated radiation therapy. Rates were no different by treatment group (p = 0.30) (A) or when patients were stratified by tumor histologic type (p = 0.29 for adenocarcinoma [B] or p = 0.90 for squamous cell carcinoma [C]). Patients with adenocarcinoma with a pathologic complete response to chemoradiation seemed to have better local control after simultaneous integrated boost–intensity-modulated radiation therapy than after convention-dose therapy, but this apparent difference was not statistically significant (p = 0.22) (D).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions